rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PHVS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Pharvaris at guggenheim healthcare conference: oral HAE push gains speed
      Nov 9Investing.comPHVS
      Pharvaris (PHVS) Stock Could Look Pricey Following Phase 3 Momentum
      Nov 4Yahoo FinancePHVS
      Pharvaris N.V. (PHVS) Presents at 2026 HAEi Regional Conference Americas - Slideshow
      Oct 26Seeking AlphaPHVS
      Pharvaris N.V. (PHVS) Presents at 2026 HAEi Regional Conference Americas - Slideshow (NASDAQ:PHVS) 2026-10-26

      2026-10-26. The following slide deck was published by Pharvaris N.V.

      Oct 26Seeking AlphaPHVS
      Bank of America backs Pharvaris on breakthrough for rare swelling disease
      Oct 26TheStreetPHVSBAC
      Pharvaris Shares Rise After BofA Securities Upgrade
      Oct 23Yahoo FinancePHVS
      Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
      Oct 23BenzingaPHVS
      BofA upgrades Pharvaris stock rating on oral HAE treatment potential
      Oct 23Investing.comPHVS
      12 Health Care Stocks Moving In Wednesday's Pre-Market Session
      Oct 21BenzingaCALCPHVS
      Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Pharvaris (PHVS) and Tenet Healthcare (THC)

      Detailed price information for Pharvaris N.V. (PHVS-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailHSICPHVS
      Pharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 Trial

      Pharvaris (PHVS) said Thursday the phase 3 study of its experimental drug, deucrictibant, for on-dem

      Oct 9Yahoo FinancePHVS
      Pharvaris HAE drug shows faster symptom relief in Lancet study
      Oct 8Investing.comPHVS
      Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?
      Oct 8Yahoo FinancePHVS
      Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potential
      Oct 6Investing.comPHVS
      NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
      Oct 5Yahoo FinancePHVS
      What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?

      Pharvaris (NasdaqGS:PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 trial of deucrictibant XR for hereditary angioedema prevention. The study met all primary and secondary endpoints with statistical significance, supporting deucrictibant XR as a potential prophylactic treatment option. Management plans to use CHAPTER-3 data in upcoming marketing authorization applications for deucrictibant XR in hereditary angioedema. The statistically significant CHAPTER-3 outcome...

      Sep 19Yahoo FinancePHVS
      Pharvaris Insider Sold Shares Worth $1,771,125, According to a Recent SEC Filing

      Stefan Andreas Abele, Chief Technical Operations Officer, on September 15, 2026, sold 46,400 shares

      Sep 17Yahoo FinancePHVS
      Pharvaris at H.C. Wainwright conference: dual HAE push gains pace
      Sep 16Investing.comPHVS
      Pharvaris Insider Sold Shares Worth $1,023,575, According to a Recent SEC Filing

      Wim Souverijns, Chief Commercial Officer, on September 14, 2026, sold 26,090 shares in Pharvaris (PH

      Sep 16Yahoo FinancePHVS
      PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

      Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

      Sep 15Yahoo FinancePHVS
      Pharvaris at Morgan Stanley conference: oral HAE drug nears launch
      Sep 15Investing.comPHVSMS
      Cantor Fitzgerald reiterates Pharvaris stock rating after trial data
      Sep 14Investing.comPHVS
      Weekly Note: Two Approvals, Two Verdicts: Pharvaris' Oral Breakthrough Vs. Scholar Rock's Population Problem
      Sep 13Seeking AlphaPHVSSRRK
      Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?

      Pharvaris N.V. (NASDAQ:PHVS) reported on September 8 that once-daily deucrictibant extended-release tablets reduced hereditary angioedema attack rates by 83% relative to placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a 95% confidence interval of 72% to 90% and a p-value below 0.0001. The global, double-blind study randomized 85 participants to […]

      Sep 10Yahoo FinancePHVS
      Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema - Slideshow (NASDAQ:PHVS) 2026-09-10

      2026-09-10. The following slide deck was published by Pharvaris N.V.

      Sep 10Seeking AlphaPHVS
      Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum
      Sep 10Investing.comPHVS
      Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zimmer Biomet Holdings (ZBH), AdaptHealth (AHCO) and Pharvaris (PHVS)

      Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailAHCOPHVSZBH
      Guggenheim raises Pharvaris stock price target on trial results
      Sep 10Investing.comPHVS
      Pharvaris at Wells Fargo conference: oral HAE drug gains ground
      Sep 10Investing.comPHVSWFC
      Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
      Sep 9Seeking AlphaPHVS
      Pharvaris stock gets $60 target at H.C. Wainwright on trial data
      Sep 9Investing.comPHVS
      Wells Fargo raises Pharvaris stock price target on strong trial data
      Sep 9Investing.comPHVS
      Citizens raises Pharvaris stock price target to $79 on HAE therapy
      Sep 9Investing.comPHVS
      Pharvaris charts approval course for swelling disorder drug on Phase III win

      The company will seek approval for deucrictibant XR as competition in the HAE market mounts.

      Sep 9Yahoo FinancePHVS
      RBC Raises Price Target on Pharvaris to $62 From $52, Keeps Outperform, Speculative Risk

      Pharvaris (PHVS) has an average rating of buy and mean price target of $58.38, according to analysts

      Sep 9Yahoo FinancePHVS
      Pharvaris Insider Sold Shares Worth $610,134, According to a Recent SEC Filing

      Peng Lu, President, on September 08, 2026, sold 15,000 shares in Pharvaris (PHVS) for $610,134. Foll

      Sep 9Yahoo FinancePHVS
      The 'Blowout' And 'Bull Case' News That Sent Two Biotechs Flying

      Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results in lung and swelling diseases.

      Sep 8Investor's Business DailyPHVSROIV
      Oppenheimer raises Pharvaris stock price target on trial results
      Sep 8Investing.comPHVS
      Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
      Sep 8BenzingaPHVSROIVIONQ
      Why is Pharvaris stock surging today?
      Sep 8Investing.comPHVS
      Why Is Pharvaris Stock Soaring Tuesday?
      Sep 8BenzingaPHVS
      Pharvaris Shares Surge 27% After Deucrictibant Phase 3 Trial Meets Primary Endpoint

      Pharvaris (NASDAQ:PHVS) shares jumped 27% on Tuesday after the company reported positive topline results from its pivotal Phase 3 CHAPTER-3 study evaluating deucrictibant XR for the prevention of hereditary angioedema attacks. The study met its primary endpoint, with once-daily deucrictibant XR producing an 83% reduction in the HAE attack rate compared with placebo.

      Sep 8Yahoo FinancePHVS
      Pharvaris' genetic disorder drug meets main goal in late-stage trial
      Sep 8ReutersPHVS
      Pharvaris posts late-stage trial win for HAE drug (PHVS:NASDAQ)

      Pharvaris (PHVS) stock jumps as the company announces a late-stage trial for its lead asset deucrictibant XR, in hereditary angioedema. Read more here.

      Sep 8Seeking AlphaPHVS
      Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

      Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types o...

      Sep 8Business InsiderPHVS
      Pharvaris stock surges 27% on positive trial data
      Sep 8Investing.comPHVS
      Pharvaris reports positive phase 3 results for HAE drug
      Sep 8Investing.comPHVS

      This is the newest page. Registered accounts read further back.